Previous 10 | Next 10 |
NORTHAMPTON, MA / ACCESSWIRE / October 23, 2023 / Alkermes Originally published in Alkermes September 2023 Corporate Responsibility Report Alkermes' mission is to research, develop and commercialize important new medicines for patients suffering from complex medical conditions, including those...
Alkermes Presents First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress PR Newswire — Initial ALKS 2680 Data Demonstrated Dose-Dependent, Significantly Improved Sleep Latency Compared to Placebo in Narcolepsy Type 1 — — ...
Alkermes to Report Third Quarter Financial Results on October 25, 2023 PR Newswire DUBLIN , Oct. 18, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Wednesday...
NORTHAMPTON, MA / ACCESSWIRE / October 16, 2023 / Alkermes This month we recognize Global Diversity Awareness Month. On Team Alkermes, we believe that diverse voices and perspectives bring immeasurable value to our organization and the patients we serve. We remain steadfast in our commitment to...
NORTHAMPTON, MA / ACCESSWIRE / October 13, 2023 / Mental Health conditions among adults are on the rise across the country, which makes mental health screening more important than ever. Check out this helpful tool from Mental Health America that may help determine if you or a loved one are exp...
NORTHAMPTON, MA / ACCESSWIRE / October 11, 2023 / Alkermes Corporate responsibility is foundational to our business. We are proud to release our latest Corporate Responsibility Report, which details our progress in 2022 related to environmental sustainability, diversity, inclusion and belonging...
Mural Oncology to Host Investor Webcast on October 17 PR Newswire — Event to be Webcast on Tuesday, October 17 at 11:00 a.m. ET — DUBLIN , Oct. 10 , 2023 /PRNewswire/ -- Mural Oncology plc , the publicly-traded oncology company t...
Alkermes to Present First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress PR Newswire — Oral Presentation to Include Initial Clinical Proof-of-Concept Data in Patients With Narcolepsy Type 1 for ALKS 2680, the Company's Investigational Orex...
2023-10-04 12:32:07 ET More on Harmony Biosciences Harmony Biosciences: A Balancing Act As Investors Lose Some Sleep Harmony Biosciences Holdings, Inc. 2023 Q2 - Results - Earnings Call Presentation Harmony Biosciences Holdings, Inc. (HRMY) Q2 2023 Earnings Call Tran...
NORTHAMPTON, MA / ACCESSWIRE / September 21, 2023 / Alkermes September is Ovarian Cancer Awareness Month. We stand in solidarity with patients, caregivers and family members whose lives have been impacted by Ovarian Cancer. Our oncology team is dedicated to advancing research and developing pot...
News, Short Squeeze, Breakout and More Instantly...
Alkermes to Report Second Quarter Financial Results on July 24, 2024 PR Newswire DUBLIN , July 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Wednesday, ...
2024-06-29 16:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-19 17:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...